Common Stock, par value $0.0001
- Symbol
- NTHI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
NeOnc Technologies Holdings, Inc.
NTHINASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 16, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release announcing early clinical improvement in its first patient treated in Abu Dhabi, United Arab Emirates, with investigational intranasal NEO100 through the Company’s Compassionate Care program. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.
Current securities
Recent company filings
- Results of Operations and Financial Condition · Regulation FD DisclosureNov 5, 2026
- 10-Q filingNov 5, 2026
- Regulation FD DisclosureNov 3, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 15, 2026
- Regulation FD DisclosureSep 28, 2026
Registered securities in this filing
NEONC TECHNOLOGIES HOLDINGS, INC. · 8-K · Filed 2026-10-22
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On October 16, 2026, NeOnc Technologies Holdings,
Inc. (the “Company”) issued a press release announcing early clinical improvement in its first patient treated in Abu Dhabi,
United Arab Emirates, with investigational intranasal NEO100 through the Company’s Compassionate Care program. A copy of the press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
On October 21, 2026, the Company issued a press
release announcing that it has signed a Memorandum of Understanding (MoU) with the Department of Health - Abu Dhabi (DoH) to cooperate
on the development of research and clinical capability in oncology and central nervous system therapeutics in the Emirate of Abu Dhabi.
A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
On October 22, 2026, the Company issued a press
release announcing that it will be featured on Health Uncensored with Dr. Drew, a national health television series hosted by Dr. Drew
Pinsky, in a segment on non-invasive approaches to delivering investigational therapies to brain tumors. A copy of the press release is
furnished as Exhibit 99.3 to this Current Report on Form 8-K.
The information in this Item 7.01,
Exhibit 99.1, Exhibit 99.2, and Exhibit 99.3 furnished hereto shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a filing.
Filed exhibits (2)
Exhibit 99.1 NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi Treating physicians report that a critically ill three-year-old boy is breathing independently and showing renewed movement following initiation of investigational treatment CALABASAS, Calif., Oct. 16, 2026 - NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced early clinical improvement in its first patient treated in Abu Dhabi, United Arab Emirates, with investigational intranasal NEO100 through the Company’s Compassionate Care program. According to his treating physicians, the patient, a critically ill three-year-old boy with an aggressive brain tumor, is now breathing independently without ventilator support and beginning to move his legs following initiation of treatment. These early observations involve one patient receiving compassionate-use treatment and do not establish that NEO100 caused the improvement or predict outcomes in other patients. “Hearing that this little boy is breathing on his own and be…
Open exhibit ↗Exhibit 99.2 NeOnc Technologies and the Department of Health - Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration Proposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment of clinical trial opportunities and a potential regional presence for NeOnc in Abu Dhabi Two children in Abu Dhabi are receiving investigational NEO100 through NeOnc’s Compassionate Care program, with a third expected this week CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 21, 2026 - NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it has signed a Memorandum of Understanding (MoU) with the Department of Health - Abu Dhabi (DoH) to cooperate on the development of research and clinical capability in oncology and central nervous system therapeutics in the Emirate of Abu Dhabi. The MoU was signed on the sidelines of the Abu Dhabi Future Health Summit (ADFHS) 2026. Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc T…
Open exhibit ↗